{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:10:00Z","timestamp":1780578600588,"version":"3.54.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chang Gung Memorial Foundation","award":["CMRPG3L1611"],"award-info":[{"award-number":["CMRPG3L1611"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The albumin\u2013bilirubin (ALBI) score objectively reflects hepatic functional reserve and is widely used as a prognostic biomarker in hepatocellular carcinoma. However, its prognostic value in patients with biliary tract carcinoma (BTC) treated with durvalumab plus gemcitabine\u2013cisplatin (GCD) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 172 patients with unresectable or metastatic BTC who received first-line GCD between 2021 and 2025. Baseline ALBI scores were calculated and patients were stratified into cohort-specific tertiles (Q1-Q3). Overall survival (OS) was estimated using Kaplan\u2013Meier method and Cox regression hazards models. Predictive performance for OS was compared between ALBI and the Eastern Cooperative Oncology Group performance status (ECOG PS) using time-dependent area under the receiver operating characteristic curves (AUC) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median OS was 13.8\u2009months (95% CI, 9.9-17.7). Survival differed significantly across ALBI tertiles: median OS was 24.0\u2009months (95% CI, 10.3-37.8) for Q1, 14.4\u2009months (95% CI, 9.2-19.6) for Q2, and 5.9\u2009months (95% CI, 2.5-9.2) for Q3 (P\u2009&amp;lt;\u2009.001). In multivariate analysis, ALBI remained an independent prognostic factor for OS (Q3 vs Q1, adjusted hazard ratio 2.16; 95% CI, 1.16-4.04; P\u2009=\u2009.016). The ALBI score demonstrated improved prognostic discrimination (AUC 0.714 at 6\u2009months; 0.656 at 12\u2009months) compared with ECOG PS (AUC 0.591 and 0.551, respectively). Tumor response rates were similar across tertiles, but higher ALBI scores were associated with an increased incidence of grade \u22653 toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pretreatment ALBI score is a simple, objective, and independent prognostic biomarker for patients with advanced BTC receiving durvalumab-based immunochemotherapy. Incorporating ALBI into baseline assessment may help identify high-risk patients who warrant closer monitoring or individualized therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag179","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:28:01Z","timestamp":1777980481000},"source":"Crossref","is-referenced-by-count":0,"title":["The albumin\u2013bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy"],"prefix":"10.1093","volume":"31","author":[{"given":"Ming-Yang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of General Surgery, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]},{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]},{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, Chang Gung Memorial Hospital at Keelung , Keelung 204,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chen","family":"Lan","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, New Taipei Municipal TuCheng Hospital , New Taipei City 236,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shin","family":"Hung","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-4548","authenticated-orcid":false,"given":"Wen-Chi","family":"Chou","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan 333,","place":["Taiwan"]},{"name":"Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou , Taoyuan 333,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026060408372522500_oyag179-B1","doi-asserted-by":"publisher","first-page":"102688","DOI":"10.1016\/j.canep.2024.102688","article-title":"Prognosis related to treatment plan in patients with biliary tract cancer: a nationwide database study","volume":"93","author":"Renteria Ramirez","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"2026060408372522500_oyag179-B2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2026060408372522500_oyag179-B3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2026060408372522500_oyag179-B4","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2026060408372522500_oyag179-B5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026060408372522500_oyag179-B6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"2026060408372522500_oyag179-B7","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy","volume":"31","author":"Wang","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026060408372522500_oyag179-B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00535-018-1518-3","article-title":"Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy","volume":"54","author":"Suzuki","year":"2019","journal-title":"J Gastroenterol"},{"key":"2026060408372522500_oyag179-B9","doi-asserted-by":"publisher","first-page":"e70181","DOI":"10.1111\/liv.70181","article-title":"A prognostic index for advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab: the MAGIC-D index","volume":"45","author":"Persano","year":"2025","journal-title":"Liver Int"},{"key":"2026060408372522500_oyag179-B10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12885-020-06914-1","article-title":"Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Cancer"},{"key":"2026060408372522500_oyag179-B11","doi-asserted-by":"publisher","first-page":"gow021","DOI":"10.1093\/gastro\/gow021","article-title":"Serum albumin predicts survival in patients with hilar cholangiocarcinoma","volume":"5","author":"Waghray","year":"2016","journal-title":"Gastroenterol Rep"},{"key":"2026060408372522500_oyag179-B12","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/jcm15051981","article-title":"Use of human serum albumin in critically ill patients: a narrative review","volume":"15","author":"Rubio-Baines","year":"2026","journal-title":"J Clin Med"},{"key":"2026060408372522500_oyag179-B13","doi-asserted-by":"publisher","first-page":"e000042","DOI":"10.1136\/esmoopen-2016-000042","article-title":"Cancer and liver cirrhosis: implications on prognosis and management","volume":"1","author":"Pinter","year":"2016","journal-title":"ESMO Open"},{"key":"2026060408372522500_oyag179-B14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2147\/OTT.S124161","article-title":"Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma","volume":"10","author":"Zhang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2026060408372522500_oyag179-B15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.5009\/gnl240032","article-title":"Effect of biliary drainage on the prognosis of patients with hepatocellular carcinoma and bile duct invasion","volume":"18","author":"Yang","year":"2024","journal-title":"Gut Liver"},{"key":"2026060408372522500_oyag179-B16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026060408372522500_oyag179-B17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/jvh.12638","article-title":"Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis","volume":"24","author":"Chen","year":"2017","journal-title":"J Viral Hepat"},{"key":"2026060408372522500_oyag179-B18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/jgh.12938","article-title":"New simple prognostic score for primary biliary cirrhosis: albumin-bilirubin score","volume":"30","author":"Chan","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2026060408372522500_oyag179-B19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12876-025-04117-1","article-title":"Prognostic value of ALBI score for all-cause mortality in metabolic associated fatty liver disease patients: a cohort study from NHANES 2003\u20132018","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026060408372522500_oyag179-B20","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.jhepr.2021.100347","article-title":"ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","volume":"3","author":"Demirtas","year":"2021","journal-title":"JHEP Rep"},{"key":"2026060408372522500_oyag179-B21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12029-022-00832-0","article-title":"Clinical utility of albumin bilirubin grade as a prognostic marker in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a systematic review and meta-analysis","volume":"54","author":"Mishra","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"2026060408372522500_oyag179-B22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.21037\/atm.2020.02.85","article-title":"Comparison between Child-Pugh score and albumin-bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026060408372522500_oyag179-B23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12876-025-03979-9","article-title":"The prognostic role of albumin-bilirubin grade in the mortality of extrahepatic cholangiocarcinoma patients","volume":"25","author":"Dayyan","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026060408372522500_oyag179-B24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12957-025-03813-2","article-title":"Prognostic impact of albumin-bilirubin score in predicting the long-term survival of distal cholangiocarcinoma after radical surgery","volume":"23","author":"Huang","year":"2025","journal-title":"World J Surg Oncol"},{"key":"2026060408372522500_oyag179-B25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026060408372522500_oyag179-B26"},{"key":"2026060408372522500_oyag179-B27","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae306","article-title":"Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer","volume":"30","author":"Huang","year":"2025","journal-title":"Oncologist"},{"key":"2026060408372522500_oyag179-B28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00432-025-06239-1","article-title":"Treatment with gemcitabine\/cisplatin and durvalumab for advanced biliary tract cancer\u2014real-world data from a multicenter German patient population","volume":"151","author":"Gerhardt","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026060408372522500_oyag179-B29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11523-024-01044-1","article-title":"Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data","volume":"19","author":"Olkus","year":"2024","journal-title":"Target Oncol"},{"key":"2026060408372522500_oyag179-B30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1159\/000541891","article-title":"Survival outcomes of durvalumab in combination with cisplatin and gemcitabine in advanced biliary tract cancer: real-world results from a single Italian institution","volume":"103","author":"Rimini","year":"2025","journal-title":"Oncology"},{"key":"2026060408372522500_oyag179-B31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.21037\/jgo.2016.09.17","article-title":"Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function","volume":"8","author":"Gong","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"2026060408372522500_oyag179-B32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/cas.12851","article-title":"Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction","volume":"107","author":"Shibata","year":"2016","journal-title":"Cancer Sci"},{"key":"2026060408372522500_oyag179-B33","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","article-title":"Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565","volume":"18","author":"Venook","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026060408372522500_oyag179-B34","doi-asserted-by":"publisher","first-page":"1482291","DOI":"10.3389\/fimmu.2024.1482291","article-title":"Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints","volume":"15","author":"Dai","year":"2024","journal-title":"Front Immunol"},{"key":"2026060408372522500_oyag179-B35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"2026060408372522500_oyag179-B36","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.3390\/ijms25179522","article-title":"The impact of liver failure on the immune system","volume":"25","author":"D\u0105browska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026060408372522500_oyag179-B37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/bmjspcare-2019-002080","article-title":"Inter-rater reliability in performance status assessment between clinicians and patients: a systematic review and meta-analysis","volume":"10","author":"Chow","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"2026060408372522500_oyag179-B38","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2004.11.015","article-title":"Assessment of the prognosis of cirrhosis: child-Pugh versus MELD","volume":"42","author":"Durand","year":"2005","journal-title":"J Hepatol"},{"key":"2026060408372522500_oyag179-B39","doi-asserted-by":"publisher","first-page":"e170117","DOI":"10.1001\/jamasurg.2017.0117","article-title":"Development and validation of a prognostic score for intrahepatic cholangiocarcinoma","volume":"152","author":"Raoof","year":"2017","journal-title":"JAMA Surg"},{"key":"2026060408372522500_oyag179-B40","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1248\/bpb.b22-00608","article-title":"Usefulness of the albumin-bilirubin score in determining the initial dose of voriconazole for patients with liver cirrhosis","volume":"46","author":"Nashimoto","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"2026060408372522500_oyag179-B41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.surge.2019.09.002","article-title":"Clinical application of albumin-bilirubin (ALBI) score: the current status","volume":"18","author":"Deng","year":"2020","journal-title":"Surgeon"},{"key":"2026060408372522500_oyag179-B42","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag179\/68238835\/oyag179.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag179\/68238835\/oyag179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag179\/68238835\/oyag179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:37:35Z","timestamp":1780576655000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag179\/8671865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag179","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,7]]},"article-number":"oyag179"}}